nach oben

Endocrine

Erschienen in:

06.01.2022 | Original Article

Proteolytic activation of anti-Müllerian hormone is suppressed in adolescent girls

verfasst von: Michael W. Pankhurst, Peter W. Dillingham, Alexia S. Peña

Erschienen in: Endocrine | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The ratio of the anti-Müllerian hormone (AMH) precursor (proAMH) to active AMH (AMH_N,C) is higher in childhood than in adulthood but has never been quantified during adolescence. The ratio of proAMH to total AMH (AMH prohormone index, API) was examined during the puberty in healthy girls. The API was also compared between girls with and without polycystic ovary syndrome (PCOS) to determine if there were differences that could assist in PCOS diagnosis during adolescence.

Methods

Total AMH and proAMH were measured by immunoassay in a single-centre, cross-sectional observational study; 61 controls and 29 girls with PCOS were included in the study (age range 8–21 years). The API was calculated as proAMH as a percentage of total AMH. Differences in API between control and PCOS subjects and across age-groups were examined by Welch’s ANOVA. The relationship between API and a range of metabolic parameters was examined by Pearson correlation.

Results

The API in healthy females increased between the ages of 10~15 years and declined from 15~20 years (p < 0.001). The API was negatively correlated with body mass index in the control (p = 0.04) and PCOS groups (p = 0.007). The API was associated with factors related to adiposity and lipid metabolism. The API was not significantly different in control girls and girls with PCOS.

Conclusions

Higher API during adolescence suggests that proteolytic activation of proAMH is suppressed during this life stage. API was not different between control girls and girls with PCOS indicating that it is not useful in diagnosis of PCOS during adolescence.

C. Weenen, J.S. Laven, A.R. Von Bergh, M. Cranfield, N.P. Groome, J.A. Visser, P. Kramer, B.C. Fauser, A.P. Themmen, Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol. Hum. Reprod. 10(2), 77–83 (2004)CrossRef

J.V. Jeppesen, R.A. Anderson, T.W. Kelsey, S.L. Christiansen, S.G. Kristensen, K. Jayaprakasan, N. Raine-Fenning, B.K. Campbell, C. Yding Andersen, Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol. Hum. Reprod. 19(8), 519–527 (2013). https://doi.org/10.1093/molehr/gat024CrossRefPubMed

D. Dewailly, C.Y. Andersen, A. Balen, F. Broekmans, N. Dilaver, R. Fanchin, G. Griesinger, T.W. Kelsey, A. La Marca, C. Lambalk, H. Mason, S.M. Nelson, J.A. Visser, W.H. Wallace, R.A. Anderson, The physiology and clinical utility of anti-Mullerian hormone in women. Hum. Reprod. Update 20(3), 370–385 (2014). https://doi.org/10.1093/humupd/dmt062CrossRefPubMed

H.J. Teede, M.L. Misso, M.F. Costello, A. Dokras, J. Laven, L. Moran, T. Piltonen, R.J. Norman, P.N. International, Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 110(3), 364–379 (2018). https://doi.org/10.1016/j.fertnstert.2018.05.004CrossRefPubMedPubMedCentral

A.S. Pena, S.F. Witchel, K.M. Hoeger, S.E. Oberfield, M.G. Vogiatzi, M. Misso, R. Garad, P. Dabadghao, H. Teede, Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med. 18(1), 72 (2020). https://doi.org/10.1186/s12916-020-01516-xCrossRefPubMedPubMedCentral

E. Codner, C. Villarroel, F.C. Eyzaguirre, P. Lopez, P.M. Merino, F. Perez-Bravo, G. Iniguez, F. Cassorla, Polycystic ovarian morphology in postmenarchal adolescents. Fertil. Steril. 95(2), 702–706 (2011). https://doi.org/10.1016/j.fertnstert.2010.06.015. e701-702CrossRefPubMed

R. Hart, D.A. Doherty, R.J. Norman, S. Franks, J.E. Dickinson, M. Hickey, D.M. Sloboda, Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil. Steril. 94(3), 1118–1121 (2010). https://doi.org/10.1016/j.fertnstert.2009.11.002CrossRefPubMed

A.B. Sopher, G. Grigoriev, D. Laura, T. Cameo, J.P. Lerner, R.J. Chang, D.J. McMahon, S.E. Oberfield, Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents. J. Pediatr. Endocrinol. Metab. 27(11-12), 1175–1179 (2014). https://doi.org/10.1515/jpem-2014-0128CrossRefPubMedPubMedCentral

A. Tokmak, H. Timur, R.T. Aksoy, M. Cinar, N. Yilmaz, Is anti-Mullerian hormone a good diagnostic marker for adolescent and young adult patients with Polycystic ovary syndrome? Turk. J. Obstet. Gynecol. 12(4), 199–204 (2015). https://doi.org/10.4274/tjod.21549CrossRefPubMedPubMedCentral

10.

A. Yetim, C. Yetim, F. Bas, O.B. Erol, G. Cig, A. Ucar, F. Darendeliler, Anti-mullerian hormone and inhibin-A, but not inhibin-B or insulin-like peptide-3, may be used as surrogates in the diagnosis of polycystic ovary syndrome in adolescents: preliminary results. J. Clin. Res. Pediatr. Endocrinol. 8(3), 288–297 (2016). https://doi.org/10.4274/jcrpe.3253CrossRefPubMedPubMedCentral

11.

J.Y. Kim, H. Tfayli, S.F. Michaliszyn, S. Lee, A. Nasr, S. Arslanian, Anti-mullerian hormone in obese adolescent girls with polycystic ovary syndrome. J. Adolesc. Health 60(3), 333–339 (2017). https://doi.org/10.1016/j.jadohealth.2016.10.015CrossRefPubMed

12.

R.L. Cate, R.J. Mattaliano, C. Hession, R. Tizard, N.M. Farber, A. Cheung, E.G. Ninfa, A.Z. Frey, D.J. Gash, E.P. Chow, R. Fischer, J. Bertonis, G. Torres, B. Wallner, K. Rmachandran, R. Ragin, T. Manganaro, D. MacLaughlin, P. Donahoe, Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 45, 685–698 (1986)CrossRef

13.

N. di Clemente, S.P. Jamin, A. Lugovskoy, P. Carmillo, C. Ehrenfels, J.Y. Picard, A. Whitty, N. Josso, R.B. Pepinsky, R.L. Cate, Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta. Mol. Endocrinol. 24(11), 2193–2206 (2010). https://doi.org/10.1210/me.2010-0273CrossRefPubMedPubMedCentral

14.

C.A. Wilson, N. di Clemente, C. Ehrenfels, R.B. Pepinsky, N. Josso, B. Vigier, R.L. Cate, Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily. Mol. Endocrinol. 7, 247–257 (1993). https://doi.org/10.1210/me.7.2.247CrossRefPubMed

15.

M.W. Pankhurst, I.S. McLennan, Human blood contains both the uncleaved precursor of anti-Mullerian hormone and a complex of the NH2- and COOH-terminal peptides. Am. J. Physiol. Endocrinol. Metab. 305(10), E1241–1247 (2013). https://doi.org/10.1152/ajpendo.00395.2013CrossRefPubMed

16.

M.W. Pankhurst, Y.H. Chong, I.S. McLennan, Relative levels of the proprotein and cleavage-activated form of circulating human anti-Mullerian hormone are sexually dimorphic and variable during the life cycle. Physiol. Rep. 4(9), e12783 (2016). https://doi.org/10.14814/phy2.12783CrossRefPubMedPubMedCentral

17.

M.M. Devillers, F. Petit, V. Cluzet, C.M. Francois, F. Giton, G. Garrel, J. Cohen-Tannoudji, C.J. Guigon, FSH inhibits AMH to support ovarian estradiol synthesis in infantile mice. J. Endocrinol. 240(2), 215–228 (2019). https://doi.org/10.1530/JOE-18-0313CrossRefPubMed

18.

C.M. Francois, F. Petit, F. Giton, A. Gougeon, C. Ravel, S. Magre, J. Cohen-Tannoudji, C.J. Guigon, A novel action of follicle-stimulating hormone in the ovary promotes estradiol production without inducing excessive follicular growth before puberty. Sci. Rep. -Uk 11(7), 46222 (2017). https://doi.org/10.1038/srep46222CrossRef

19.

L. Cui, Y. Qin, X. Gao, J. Lu, L. Geng, L. Ding, Z. Qu, X. Zhang, Z.J. Chen, Antimullerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause. Fertil. Steril. 105(2), 481–485 e481 (2016). https://doi.org/10.1016/j.fertnstert.2015.10.017CrossRefPubMed

20.

T.W. Kelsey, P. Wright, S.M. Nelson, R.A. Anderson, W.H. Wallace, A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One 6(7), e22024 (2011). https://doi.org/10.1371/journal.pone.0022024CrossRefPubMedPubMedCentral

21.

C.P. Hagen, L. Aksglaede, K. Sorensen, A. Mouritsen, A.M. Andersson, J.H. Petersen, K.M. Main, A. Juul, Individual serum levels of anti-Mullerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum. Reprod. 27(3), 861–866 (2012). https://doi.org/10.1093/humrep/der435CrossRefPubMed

22.

M.W. Pankhurst, S. Shorakae, R.J. Rodgers, H.J. Teede, L.J. Moran, Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimullerian hormone isoforms (proAMH and AMHN,C). Fertil. Steril. 108(5), 851–857 e852 (2017). https://doi.org/10.1016/j.fertnstert.2017.08.012CrossRefPubMed

23.

C.L. Ogden, K.M. Flegal, M.D. Carroll, C.L. Johnson, Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 288(14), 1728–1732 (2002). https://doi.org/10.1001/jama.288.14.1728kCrossRefPubMed

24.

M.W. Pankhurst, I.S. McLennan, A specific immunoassay for proAMH, the uncleaved proprotein precursor of anti-Mullerian hormone. Mol. Cell Endocrinol. 419, 165–171 (2016). https://doi.org/10.1016/j.mce.2015.10.013CrossRefPubMed

25.

A.S. Pena, E. Wiltshire, K. MacKenzie, R. Gent, L. Piotto, C. Hirte, J. Couper, Vascular endothelial and smooth muscle function relates to body mass index and glucose in obese and nonobese children. J. Clin. Endocrinol. Metab. 91(11), 4467–4471 (2006). https://doi.org/10.1210/jc.2006-0863CrossRefPubMed

26.

J. Fox, S. Weisberg, An R Companion to Applied Regression, Third edition ed. SAGE Publication, (2018)

27.

R Core Team: A language and environment for statistical computing. R Foundation for Statistical Computing V. http://www.R-project.org (2020). Accessed 2020

28.

M. Peigné, P. Pigny, M.W. Pankhurst, E. Drumez, A. Loyens, D. Dewailly, S. Catteau-Jonard, P. Giacobini, The proportion of cleaved Anti-Müllerian Hormone (AMH) is higher in the serum but not in the follicular fluid of obese women independently of Polycystic Ovary Syndrome (PCOS). Reproductive BioMedicine Online (2020). https://doi.org/10.1016/j.rbmo.2020.07.020

29.

M.W. Pankhurst, Y.H. Chong, Variation in circulating antimullerian hormone precursor during the periovulatory and acute postovulatory phases of the human ovarian cycle. Fertil. Steril. 106(5), 1238–1243 e1232 (2016). https://doi.org/10.1016/j.fertnstert.2016.06.010CrossRefPubMed

30.

H.L. Hambridge, S.L. Mumford, D.R. Mattison, A. Ye, A.Z. Pollack, M.S. Bloom, P. Mendola, K.L. Lynch, J. Wactawski-Wende, E.F. Schisterman, The influence of sporadic anovulation on hormone levels in ovulatory cycles. Hum. Reprod. 28(6), 1687–1694 (2013). https://doi.org/10.1093/humrep/det090CrossRefPubMedPubMedCentral

31.

R.A. Anderson, M. McLaughlin, W.H. Wallace, D.F. Albertini, E.E. Telfer, The immature human ovary shows loss of abnormal follicles and increasing follicle developmental competence through childhood and adolescence. Hum. Reprod. 29(1), 97–106 (2014). https://doi.org/10.1093/humrep/det388CrossRefPubMed

32.

B.K. Campbell, M. Clinton, R. Webb, The role of anti-Mullerian hormone (AMH) during follicle development in a monovulatory species (sheep). Endocrinology 153(9), 4533–4543 (2012). https://doi.org/10.1210/en.2012-1158CrossRefPubMed

33.

J.K. Rodrigues, P.A. Navarro, M.B. Zelinski, R.L. Stouffer, J. Xu, Direct actions of androgens on the survival, growth and secretion of steroids and anti-Mullerian hormone by individual macaque follicles during three-dimensional culture. Hum. Reprod. 30(3), 664–674 (2015). https://doi.org/10.1093/humrep/deu335CrossRefPubMedPubMedCentral

34.

J. Xu, C.V. Bishop, M.S. Lawson, B.S. Park, F. Xu, Anti-Mullerian hormone promotes pre-antral follicle growth, but inhibits antral follicle maturation and dominant follicle selection in primates. Hum. Reprod. 31(7), 1522–1530 (2016). https://doi.org/10.1093/humrep/dew100CrossRefPubMedPubMedCentral

35.

W. Zheng, H. Zhang, N. Gorre, S. Risal, Y. Shen, K. Liu, Two classes of ovarian primordial follicles exhibit distinct developmental dynamics and physiological functions. Hum. Mol. Genet. 23(4), 920–928 (2014). https://doi.org/10.1093/hmg/ddt486CrossRefPubMed

36.

J.A. Bae, H.J. Park, Y.M. Seo, J. Roh, A.J. Hsueh, S.Y. Chun, Hormonal regulation of proprotein convertase subtilisin/kexin type 5 expression during ovarian follicle development in the rat. Mol. Cell Endocrinol. 289(1-2), 29–37 (2008). https://doi.org/10.1016/j.mce.2008.04.006CrossRefPubMed

37.

M.W. Nachtigal, H.A. Ingraham, Bioactivation of Mullerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc. Natl Acad. Sci. USA 93(15), 7711–7716 (1996)CrossRef

38.

R.B. Pepinsky, L.K. Sinclair, E.P. Chow, R.J. Mattaliano, T.F. Manganaro, P.K. Donahoe, R.L. Cate, Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. J. Biol. Chem. 263(35), 18961–18964 (1988)CrossRef

Titel: Proteolytic activation of anti-Müllerian hormone is suppressed in adolescent girls
verfasst von: Michael W. Pankhurst
Peter W. Dillingham
Alexia S. Peña
Publikationsdatum: 06.01.2022
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02955-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Proteolytic activation of anti-Müllerian hormone is suppressed in adolescent girls

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group

Metformin exerts an antitumoral effect on papillary thyroid cancer cells through altered cell energy metabolism and sensitized by BACH1 depletion

A case of papillary thyroid carcinoma with Graves ophthalmopathy evaluated by 68Ga-FAPI PET/CT

Accuracy of Doppler assessment of the uterine arteries in healthy girls for the diagnosis of pubertal onset

Relationship between the ApoB/ApoA-I ratio trajectory and risk of type 2 diabetes in China: a retrospective cohort study

Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin